To explore the clinical implications of METTL3 expression in breast cancer, particularly if its expression levels can distinguish breast cancer subtypes and histological grades, we assessed METTL3 expression in a cohort of 291 breast cancer patients. This evidence concerns the gene METTL3 and breast cancer.